UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Androgen receptor-binding sites are highly mutated in prostate cancer

Nature communications, 2020-02, Vol.11 (1), p.832-10, Article 832

2020

Volltextzugriff (PDF)

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

European urology, 2018-01, Vol.73 (1), p.4-8

2018

Volltextzugriff (PDF)

Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies

International journal of molecular sciences, 2020-08, Vol.21 (16), p.5847

2020

Volltextzugriff (PDF)

Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models

The Journal of clinical investigation, 2020-02, Vol.130 (2), p.699-714

2020

Volltextzugriff (PDF)

Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer

International journal of molecular sciences, 2020-11, Vol.21 (21), p.8277

2020

Volltextzugriff (PDF)

Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor

International journal of molecular sciences, 2021-03, Vol.22 (5), p.2493

2021

Volltextzugriff (PDF)

Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer

European journal of medicinal chemistry, 2018-12, Vol.160, p.108-119

2018

Volltextzugriff (PDF)

Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer

Molecules (Basel, Switzerland), 2019-02, Vol.24 (4), p.763

2019

Volltextzugriff (PDF)

Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer

International journal of molecular sciences, 2022-02, Vol.23 (5), p.2588

2022

Volltextzugriff (PDF)

Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer

International journal of molecular sciences, 2013-06, Vol.14 (6), p.12496-12519

2013

Volltextzugriff (PDF)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics

Frontiers in oncology, 2021-02, Vol.10, p.633142

2021

Volltextzugriff (PDF)

Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer

Nature communications, 2022-08, Vol.13 (1), p.4760-4760, Article 4760

2022

Volltextzugriff (PDF)

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients

Cancers, 2021-06, Vol.13 (12), p.2939

2021

Volltextzugriff (PDF)

Discovery of Novel Lin28 Inhibitors to Suppress Cancer Cell Stemness

Cancers, 2022-11, Vol.14 (22), p.5687

2022

Volltextzugriff (PDF)

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions

Molecular cancer therapeutics, 2017-10, Vol.16 (10), p.2281-2291

2017

Volltextzugriff (PDF)

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer

Cancers, 2021-07, Vol.13 (14), p.3488

2021

Volltextzugriff (PDF)

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy

Cancers, 2021-07, Vol.13 (15), p.3675

2021

Volltextzugriff (PDF)

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers

International journal of molecular sciences, 2018-02, Vol.19 (2), p.579

2018

Volltextzugriff (PDF)

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

Cells (Basel, Switzerland), 2022-09, Vol.11 (18), p.2785

2022

Volltextzugriff (PDF)

The PHD finger of human UHRF1 reveals a new subgroup of unmethylated histone H3 tail readers

PloS one, 2011-11, Vol.6 (11), p.e27599-e27599

2011

Volltextzugriff (PDF)

Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor

Methods in molecular biology (Clifton, N.J.), 2016-01, Vol.1443, p.31

2016

Volltextzugriff (PDF)

Androgen receptor plasticity and its implications for prostate cancer therapy

Cancer treatment reviews, 2019-12, Vol.81, p.101871-101871, Article 101871

2019

Volltextzugriff (PDF)

PurificationDB: database of purification conditions for proteins

Database : the journal of biological databases and curation, 2023-04, Vol.2023

2023

Volltextzugriff (PDF)

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

Genome Biology, 2016-01, Vol.17 (1), p.10-10, Article 10

2016

Volltextzugriff (PDF)

Novel Inhibitors of androgen receptor's DNA binding domain identified using an ultra-large virtual screening

Molecular informatics, 2023-08, Vol.42 (8-9), p.e2300026-e2300026

2023

Volltextzugriff (PDF)

1 – 25 von 51

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(47)
Mit Volltextzugriff
(48)

Publikationsform

Artikel
(51)

Sprache

Englisch
(51)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Androgen receptor-binding sites are highly mutated in prostate cancer

Moving Towards Precision Urologic Oncology: Targeting Enzalutamide-resistant Prostate Cancer and Mutated Forms of the Androgen Receptor Using the Novel Inhibitor Darolutamide (ODM-201)

Deep Learning Modeling of Androgen Receptor Responses to Prostate Cancer Therapies

Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models

Dual-Inhibitors of N-Myc and AURKA as Potential Therapy for Neuroendocrine Prostate Cancer

Development of Novel Inhibitors Targeting the D-Box of the DNA Binding Domain of Androgen Receptor

Computer-aided drug discovery of Myc-Max inhibitors as potential therapeutics for prostate cancer

Computer-Aided Discovery of Small Molecules Targeting the RNA Splicing Activity of hnRNP A1 in Castration-Resistant Prostate Cancer

Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer

Targeting alternative sites on the androgen receptor to treat castration-resistant prostate cancer

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics

Reformation of the chondroitin sulfate glycocalyx enables progression of AR-independent prostate cancer

Evaluation of Darolutamide (ODM201) Efficiency on Androgen Receptor Mutants Reported to Date in Prostate Cancer Patients

Discovery of Novel Lin28 Inhibitors to Suppress Cancer Cell Stemness

Bypassing Drug Resistance Mechanisms of Prostate Cancer with Small Molecules that Target Androgen Receptor-Chromatin Interactions

Development of an Androgen Receptor Inhibitor Targeting the N-Terminal Domain of Androgen Receptor for Treatment of Castration Resistant Prostate Cancer

Optimization of New Catalytic Topoisomerase II Inhibitors as an Anti-Cancer Therapy

Benzothiophenone Derivatives Targeting Mutant Forms of Estrogen Receptor-α in Hormone-Resistant Breast Cancers

Structure-Based Study to Overcome Cross-Reactivity of Novel Androgen Receptor Inhibitors

The PHD finger of human UHRF1 reveals a new subgroup of unmethylated histone H3 tail readers

Drug-Discovery Pipeline for Novel Inhibitors of the Androgen Receptor

Androgen receptor plasticity and its implications for prostate cancer therapy

PurificationDB: database of purification conditions for proteins

Functional analysis of androgen receptor mutations that confer anti-androgen resistance identified in circulating cell-free DNA from prostate cancer patients

Novel Inhibitors of androgen receptor's DNA binding domain identified using an ultra-large virtual screening

Suchergebnisse filtern